Stephens analyst Jeff Garro initiated coverage of Accolade with an Overweight rating and $18 price target, calling it the "leader in the secular growth opportunity to deliver a better and more cost-effective healthcare experience for individual members and their sponsor." The firm views the stock as undervalued compared to peers based on the company’s growth and what the firm sees as the "likelihood of achieving its target profitability within a foreseeable period."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACCD:
- Accolade to Announce Fiscal Fourth Quarter 2023 Financial Results
- Accolade price target raised to $14.50 from $12.50 at BofA
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Accolade upgraded at Guggenheim after benefits survey, management meetings
- Accolade upgraded to Buy from Neutral at Guggenheim
